Target antibiotics Opportunity to position SNIPR Biome’s CRISPR-based therapies as solutions for antibiotic-resistant infections, aligning with hospital procurement for MDR pathogens and infection control programs.

Phage and CRISPR synergy Leverage potential co-development or integration discussions with phage therapy players and CRISPR medicine providers to expand market reach in specialized infections, including Pseudomonas and MDR E. coli.

Funding credibility Highlight recent Series B funding and substantial grants to build confidence with investors, research partners, and pharmaceutical collaborators; use milestones to drive partnership timelines.

Clinical trial momentum Capitalize on ongoing Phase I/II trials and collaborations with CF Foundation to engage biopharma, contract research organizations, and academic consortia for joint development, manufacturing, or trial support.

Healthcare partnerships Target institutions and payers seeking innovative antimicrobials; tailor outreach to hospital systems, research hospitals, and life sciences distributors that support infectious disease programs and unmet medical needs.